이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

급성 척수 손상에서 경피적 경골 신경 자극 (TASCI)

2026년 11월 2일 업데이트: University of Zurich

급성 척수 손상 환자의 경피 경골 신경 자극으로 신경인성 배뇨근 과활동을 예방: 전국 무작위, 가짜 대조, 이중 맹검 임상 시험

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

연구 개요

연구 유형

중재적

등록 (추정된)

114

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Basel, 스위스
        • 모병
        • REHAB Basel
        • 연락하다:
        • 수석 연구원:
          • Sandra Möhr, pract. med.
      • Nottwil, 스위스
        • 모병
        • Swiss Paraplegic Centre
        • 연락하다:
        • 수석 연구원:
          • Jürgen Pannek, Prof. Dr. med.
      • Sion, 스위스
        • 모병
        • Spinal Cord Injury Department, Clinique romande de réadaption
        • 연락하다:
        • 수석 연구원:
          • Xavier Jordan, Dr. med.
    • Canton of Zurich
      • Zurich, Canton of Zurich, 스위스, 8008
        • 모병
        • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital
        • 연락하다:
        • 수석 연구원:
          • Thomas M Kessler, Prof. Dr. med.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age >18 years

  • Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI) within 40 days after injury

  • Patients with acute SCI at cervical or thoracic level

  • Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)

    • no percutaneous tibial nerve stimulation (PTNS)
    • no functional electrical stimulation (FES), apart from upper limb FES
    • no electrical muscle stimulation (EMS)
  • Informed Consent

Exclusion Criteria:

  • Contraindications to the investigational product
  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
  • Treatment with antimuscarinics or with mirabegron
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: VERUM 경피 경골 신경 자극(TTNS)
  • Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
가짜 비교기: SHAM 경피 경골 신경 자극(TTNS)
  • Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The occurrence of neurogenic DO jeopardizing the upper urinary tract
기간: up to 12 months after SCI

Defined as composite measure: Urodynamic assessment establishing DO amplitude ≥40 cmH2O; or else initiation of DO treatment (with antimuscarinics and/or intradetrusor onabotulinumtoxinA injections)

up to 12 months after SCI

2차 결과 측정

결과 측정
측정값 설명
기간
요역학 검사 중 방광 순응도[mL/cmH2O]의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
요역동학 및 임상 결과와의 관계에 의해 평가된 최대 유속[mL/s]의 변화
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
요역동학 동안 비디오 촬영으로 평가한 방광요관역류(VUR)의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
요역동학 동안 근전도 검사(EMG)로 평가한 골반저 활동의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
국제 척수 학회(ISCoS) 여성/남성 성기능 데이터 세트의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
항문직장 내압 측정 및 기압계 평가 중 직장 순응도[mL/cmH2O]의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
유발전위(EP)의 신경생리학적 측정과 신경 전도 측정의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
하부요로(LUT) 신경생리학의 변화: 임상 결과와 관련된 현재 지각 역치(CPT) 및 LUT 감각 유발 전위(LUTSEP)
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
방광 조직, 혈액 및 소변의 염증 표지자의 변화 및 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
방광 조직의 변화와 임상 결과와의 관계
기간: 기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
기준선 SCI 후 3개월; SCI 후 6개월; SCI/연구 종료 후 12개월
Volumetric changes during urodynamics and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during urodynamics and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Maximum DO amplitude [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
기간: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bladder diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bowel diary parameters and their relation to clinical outcomes
기간: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bowel diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
기간: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
기간: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
기간: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes
기간: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).The NBD score is assessed by using the international spinal cord injury (ISCoS) bowel function basic data set.

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Basal internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [%, mmHg], intraabdominal pressure during defecation [mmHg]

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types of manometric patterns (I-IV) that are identified through manometric assessments

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment to quantify the severity of the spinal cord injury

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The MAS is a 5-point nominal scale that uses subjective clinical assessments of muscle tone ranging from 0 - 'No increases in tone' to 4 - 'Limb rigid in flexion or extension'. A grade of (1+) indicates resistance in the movement.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCI-SET ("Spinal Cord Injury Spasticity Evaluation Tool ") score is based on questions concerning the positive and negative effects of spasticity on different areas of daily life. Each of the 35 items are rated on a 7-point scale (-3=extremely problematic; 0=no effect; 3=extremely helpful). Calculations include counts and sum scores of areas of daily life where spasticity is problematic (count range: 0 to 35, sum score range: 35 to 0) or helpful (counts range: 0 to 35, sum score range: 0 to +35) as well as a mean score of all applicable items (range: -3 to +3)

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Fast Fourier Transformation analysis for delta, theta, alpha, beta, and gamma band power as assessed via EEG of the cortex and EMG of the muscle

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in EMG and EEG coherence measures and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Coherence for EEG and EMG signals computed as cortico-muscular, inter- and intra-muscular coherence for typical EEG/EMG frequency bands (delta, theta, alpha, beta, and gamma).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter areas are obtained by segmenting the T2*-weighted MRI images for white and gray matter at the level of LSE

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Obtained by segmenting the T2*-weighted MRI images for white and gray matter at the vertebral level C2/C3.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter volume are obtained by segmenting the T2*-weighted MRI images for white and gray matter in the CM

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in gray and white matter volume in the brain and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gray and white matter volume in the brain are computed by feeding the whole-brain T1-weighted MRI images into a voxel-based morphometry algorithm. Changes in the gray and white matter volume will be evaluated in urologically relevant brain areas.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

FA is a common dimensionless measure used in Diffusion Tensor Imaging (DTI) studies and ranges from 0, isotropic movement of water molecules (e.g., cerebrospinal fluid), to 1, fully anisotropic movement of water molecules (e.g., fiber bundles).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Mean, axial, and radial diffusivity (MD, AD, RD) are common measures used in DTI studies providing information about the integrity of the underlying tissue.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Quantitative tissue parameters assessed using MRI Multi-Parameter Mapping.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

MicroRNA (miRNA) sequencing is used to identify regulated miRNAs specific to TTNS intervention in urine and blood.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Analysis will be performed using ELISA to detect molecules likely to be involved in the underlying molecular mechanisms of neuromodulation.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes
기간: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gut and bladder microbial patterns are determined from stool and urine samples

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

기타 결과 측정

결과 측정
측정값 설명
기간
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of adverse events (AEs) and serious adverse events (SAEs) for the following categories:
기간: During complete study period, up to 12 months
  • infection - Urinary Tract Infection (UTI)
  • infection - other than UTI
  • skin irritation at the electrode site
  • irritation-related symptoms (e.g. dysuria, hematuria) immediately following a LUT intervention
  • neuro-urological deterioration
  • pressure ulcer
  • neurological deterioration
  • increase in pain
  • increase in spasticity
  • deep vein thrombosis / pulmonary embolism
  • autonomic dysreflexia
  • transfer/admittance to an acute care facility
During complete study period, up to 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Thomas M. Kessler, Prof. Dr. med., University of Zurich
  • 수석 연구원: Thomas M. Kessler, Prof. Dr. med., Balgrist University Hospital
  • 수석 연구원: Armin Curt, Prof. Dr. med., Balgrist University Hospital
  • 수석 연구원: Jürgen Pannek, Prof. Dr. med., Swiss Paraplegic Centre
  • 수석 연구원: Martin Brinkhof, Dr., Swiss Paraplegic Research, Nottwil

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 6월 19일

기본 완료 (추정된)

2028년 9월 30일

연구 완료 (추정된)

2028년 9월 30일

연구 등록 날짜

최초 제출

2019년 3월 26일

QC 기준을 충족하는 최초 제출

2019년 5월 23일

처음 게시됨 (실제)

2019년 5월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All individual participant data (IPD) and data dictionaries that underlie results in a publication are to be uploaded to a public data registry in cases where this can be done without compromising patient privacy. Given the small size of the dataset and that spinal cord injury (SCI) is a rare condition, to ensure identity protection any publicly available dataset(s) will be modified to reduce the number of indirect identifier variables, e.g. continuous variables such as age will be grouped, categorical or binary variables with small group numbers such as study centre will not be provided. When data sets cannot be sufficiently de-identified to be made publicly available, they will be made available upon reasonable request. Data judged to be confidential to participants or the participating study centers will not be released, but efforts will be made to provide scientifically meaningful equivalent information.

IPD 공유 기간

Post-publication data packages, containing the analysis data set presented in scientific reports will be available starting 6 months after the publication date. Data that are not being prepared for publication will be available to secondary users starting 4 years after study completion or discontinuation. All data will be kept for at least 10 years after study completion or discontinuation.

IPD 공유 액세스 기준

Requests for data access will be reviewed by the TASCI steering committee, which includes the four project PIs and representatives from each of the participating study centers. The steering committee will request a project plan, including at a minimum an abstract and a list of author names and roles, from the leaders of all projects wishing to use TASCI study data. Project plans will be evaluated on the basis of scientific validity, and also on whether they include adequate measures to protect patient privacy. Secondary users will be asked to sign a data use agreement.

IPD 공유 지원 정보 유형

  • ANALYTIC_CODE

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다